FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891454266> ?p ?o ?g. }

• W2891454266 endingPage "1477" @default.
• W2891454266 startingPage "1472" @default.
• W2891454266 abstract "The effectiveness of phosphodiesterase type 5 (PDE5) inhibitors over the conservative management of Peyronie's disease (PD) has been widely questioned.To determine the role of sildenafil 25 mg film formulation twice a day (S25 b.i.d.) in the improvement of curvature after treatment of collagenase of Clostridium hystoliticum (CCH) in penile curvature owing to PD.From April 2017 to April 2018, 161 consecutive patients were treated with S25 b.i.d. + CCH or CCH alone. Adjustment variables consisted of age, penile curvature, and the 15-question International Index of Erectile Function (IIEF-15) questionnaire at baseline using 1:1 propensity-score matching. Overall, 50 patients were considered subdivided into the following: 25 patients who received S25 b.i.d. + CCH (group A) and 25 who received CCH alone (group B). Patients received CCH injection using a shortened protocol and vacuum device in both groups.The primary outcome of the study was the change in penile curvature after treatment, and secondary outcomes were the change in sexual function (IIEF-15) and in the Peyronie's Disease Questionnaire (PDQ) and its subscores, PDQ-PS (psychosexual symptoms), PDQ-PP (penile pain), and PDQ-SB (symptom bother).Overall, mean penile curvature was 47.0° (SD 21.88), the mean IIEF-EF (erectile function) was 23.56 (SD 4.10), and the mean PDQ was 27.06 (SD 13.55). After the treatment, we observed a mean change for penile curvature of 25.6 (SD 9.05) in group A and -25.6 (SD 9.7) in group B (P < .01), for IIEF-EF of 2.28 (SD 2.33) in group A and 1.36 (SD 1.77) in group B (P = .03), for PDQ-PS of -3.04 (SD 2.95) in group A and of -2.12 (SD 2.06) in group B (P = .11), for PDQ-PP of -1.0 (SD 4.48) in group A and of -0.88 (SD 2.04) in group B (P = .60), for PDQ-SB of -5.84 (SD 4.58) in group A and of -4.16 (SD 4.45) in group B (P = .60), and for Female Sexual Function Index of 3.8 (SD 2.45) in group A and of 2.72 (SD 2.28) in group B (P = .14). We found a rate of global satisfaction of 70.83% in group A and of 84.0% in group B (P = .27).Addition of S25 b.i.d. to CCH is superior to CCH alone for improving penile curvature and erectile function.This is the first study comparing sildenafil + CCH vs CCH alone for the treatment of PD. Lack of randomization and direct verification of appropriate use of penile modeling could be considered limitations.In this study, combination therapy was superior in terms of penile curvature and erectile dysfunction improvement. Cocci A, Cito G, Urzì D, et al. Sildenafil 25 mg ODT + collagenase Clostridium hystoliticum vs collagenase Clostridium hystoliticum alone for the management of Peyronie's disease: A matched-pair comparison analysis. J Sex Med 2018;15:1472-1477." @default.
• W2891454266 created "2018-09-27" @default.
• W2891454266 creator A5003313880 @default.
• W2891454266 creator A5006232447 @default.
• W2891454266 creator A5017438402 @default.
• W2891454266 creator A5023670384 @default.
• W2891454266 creator A5025279590 @default.
• W2891454266 creator A5035247423 @default.
• W2891454266 creator A5037126332 @default.
• W2891454266 creator A5037830047 @default.
• W2891454266 creator A5042911985 @default.
• W2891454266 creator A5045130035 @default.
• W2891454266 creator A5046567234 @default.
• W2891454266 creator A5047342532 @default.
• W2891454266 creator A5048032405 @default.
• W2891454266 creator A5050157873 @default.
• W2891454266 creator A5053142267 @default.
• W2891454266 creator A5058330660 @default.
• W2891454266 creator A5060706639 @default.
• W2891454266 creator A5062586182 @default.
• W2891454266 creator A5075026112 @default.
• W2891454266 creator A5078919686 @default.
• W2891454266 creator A5086956059 @default.
• W2891454266 date "2018-09-20" @default.
• W2891454266 modified "2023-10-16" @default.
• W2891454266 title "Sildenafil 25 mg ODT + Collagenase <i>Clostridium hystoliticum</i> vs Collagenase <i>Clostridium hystoliticum</i> Alone for the Management of Peyronie’s Disease: A Matched-Pair Comparison Analysis" @default.
• W2891454266 cites W1970134738 @default.
• W2891454266 cites W1978968988 @default.
• W2891454266 cites W1982838484 @default.
• W2891454266 cites W2005278720 @default.
• W2891454266 cites W2060449867 @default.
• W2891454266 cites W2077803212 @default.
• W2891454266 cites W2090503365 @default.
• W2891454266 cites W2093416901 @default.
• W2891454266 cites W2107772938 @default.
• W2891454266 cites W2112997260 @default.
• W2891454266 cites W2121690051 @default.
• W2891454266 cites W2234963401 @default.
• W2891454266 cites W2325732476 @default.
• W2891454266 cites W2805012700 @default.
• W2891454266 cites W2941255854 @default.
• W2891454266 doi "https://doi.org/10.1016/j.jsxm.2018.08.012" @default.
• W2891454266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30245025" @default.
• W2891454266 hasPublicationYear "2018" @default.
• W2891454266 type Work @default.
• W2891454266 sameAs 2891454266 @default.
• W2891454266 citedByCount "30" @default.
• W2891454266 countsByYear W28914542662019 @default.
• W2891454266 countsByYear W28914542662020 @default.
• W2891454266 countsByYear W28914542662021 @default.
• W2891454266 countsByYear W28914542662022 @default.
• W2891454266 countsByYear W28914542662023 @default.
• W2891454266 crossrefType "journal-article" @default.
• W2891454266 hasAuthorship W2891454266A5003313880 @default.
• W2891454266 hasAuthorship W2891454266A5006232447 @default.
• W2891454266 hasAuthorship W2891454266A5017438402 @default.
• W2891454266 hasAuthorship W2891454266A5023670384 @default.
• W2891454266 hasAuthorship W2891454266A5025279590 @default.
• W2891454266 hasAuthorship W2891454266A5035247423 @default.
• W2891454266 hasAuthorship W2891454266A5037126332 @default.
• W2891454266 hasAuthorship W2891454266A5037830047 @default.
• W2891454266 hasAuthorship W2891454266A5042911985 @default.
• W2891454266 hasAuthorship W2891454266A5045130035 @default.
• W2891454266 hasAuthorship W2891454266A5046567234 @default.
• W2891454266 hasAuthorship W2891454266A5047342532 @default.
• W2891454266 hasAuthorship W2891454266A5048032405 @default.
• W2891454266 hasAuthorship W2891454266A5050157873 @default.
• W2891454266 hasAuthorship W2891454266A5053142267 @default.
• W2891454266 hasAuthorship W2891454266A5058330660 @default.
• W2891454266 hasAuthorship W2891454266A5060706639 @default.
• W2891454266 hasAuthorship W2891454266A5062586182 @default.
• W2891454266 hasAuthorship W2891454266A5075026112 @default.
• W2891454266 hasAuthorship W2891454266A5078919686 @default.
• W2891454266 hasAuthorship W2891454266A5086956059 @default.
• W2891454266 hasBestOaLocation W28914542662 @default.
• W2891454266 hasConcept C126322002 @default.
• W2891454266 hasConcept C126894567 @default.
• W2891454266 hasConcept C141071460 @default.
• W2891454266 hasConcept C181199279 @default.
• W2891454266 hasConcept C185592680 @default.
• W2891454266 hasConcept C2775871022 @default.
• W2891454266 hasConcept C2776768464 @default.
• W2891454266 hasConcept C2778394429 @default.
• W2891454266 hasConcept C2779145901 @default.
• W2891454266 hasConcept C2779929075 @default.
• W2891454266 hasConcept C3018271632 @default.
• W2891454266 hasConcept C55493867 @default.
• W2891454266 hasConcept C71924100 @default.
• W2891454266 hasConcept C74534348 @default.
• W2891454266 hasConceptScore W2891454266C126322002 @default.
• W2891454266 hasConceptScore W2891454266C126894567 @default.
• W2891454266 hasConceptScore W2891454266C141071460 @default.
• W2891454266 hasConceptScore W2891454266C181199279 @default.
• W2891454266 hasConceptScore W2891454266C185592680 @default.
• W2891454266 hasConceptScore W2891454266C2775871022 @default.
• W2891454266 hasConceptScore W2891454266C2776768464 @default.
• W2891454266 hasConceptScore W2891454266C2778394429 @default.
• W2891454266 hasConceptScore W2891454266C2779145901 @default.

• next